checkAd

     137  0 Kommentare Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells - Seite 3

    Contacts

    Patrick Truesdell, Vice President, Controller and Principal Accounting Officer
    Landos Biopharma
    ir@landosbiopharma.com

    Lesen Sie auch

    John Mullaly
    LifeSci Advisors, LLC
    jmullaly@lifesciadvisors.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells - Seite 3 Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid ModelsNEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) - Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing …